Jan 7 Abcuro will take an anti-KLRG1 antibody into the clinic with new funding... Abcuro will take an anti-KLRG1 antibody into the clinic with new funding, and has big plans for another. A little over two years after pu...
Jan 7 Scorpion Therapeutics strikes major $162M funding round for 'precision oncology 2.0' Less than three months after breaking cover with an impressive $102 million series A, Scorpion has whipped up another major funding round...
Jan 6 Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparat LYON, France and CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeuti...
Dec 9, 2020 ZielBio Appoints Dieter Weinand Executive Chair CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--ZielBio, Inc., an early-stage biotechnology company discovering new treatments for cancer and othe...
Dec 8, 2020 Amolyt Pharma Announces Research Collaboration with PeptiDream Amolyt and Peptidream will collaborate to optimize and evaluate growth hormone receptor antagonists to select a candidate for clinical de...
Oct 26, 2020 Scorpion Therapeutics debuts with $108M to 'put the sting in cancer' When Gary Glick, Ph.D., left the CEO post at IFM Therapeutics, he didn’t know what was next. But he soon found himself on a plane with Lo...
Oct 14, 2020 Amolyt Pharma Doses First Subject in Phase 1 Clinical Trial of Parathyroid Hormone Analog, AZP-3601, LYON, France, and NEWTON, MA, October 14, 2020 (GLOBE NEWSWIRE) — Amolyt Pharma, a global clinical-stage company specialized in developin...
Oct 6, 2020 Walden Biosciences Launches to Transform the Treatment of Kidney Disease Focused on Developing First-in-Class, Targeted Therapies to Reverse the Progression of Rare and Common Forms of Kidney Disease $51M Serie...
Sep 1, 2020 Nocion Therapeutics Advances to Clinical Stage and Expands Leadership First Subject Dosed in a Phase 1 Trial Evaluating NOC-100, a Novel Therapeutic for Cough Christopher Silber hired as Chief Medical Office...
Jun 11, 2020 Verve Therapeutics Raises $63M to Advance Gene-Editing Therapies for Heart Diseases Proceeds Will Be Used to Progress Lead Program to Phase 1 Clinical Trials and Expand Pipeline Programs CAMBRIDGE, Mass. — June 11, 2020 —...
